Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLPP | Q16740 | 5/20 | 0.59 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.59 |
| ▸ | TCF7 | P36402 | 2/20 | 0.59 |
| ▸ | BCL9 | O00512 | 1/20 | 0.59 |
| ▸ | TCF4 | P15884 | 1/20 | 0.59 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 14/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30703056 | 1.00 | CLPP (0.59) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL30364261 | 1.00 | CLPP (0.59) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL24315590 | 0.92 | CTNNB1 (0.50) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL24315608 | 0.92 | CLPP (0.59) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL24315555 | 0.90 | CLPP (0.61) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL29515574 | 0.90 | CLPP (0.61) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL25350691 | 0.88 | CLPP (0.56) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL26452242 | 0.88 | CTNNB1 (0.45) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL24315628 | 0.84 | CTNNB1 (0.49) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL24315624 | 0.84 | CLPP (0.73) | CLPPCTNNB1TCF7BCL9TCF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374020-A1 | SUBSTITUTED IMIDAZO[l,2-a]PYRAZINES AND PYRAZINO[l,2-a] PYRIMIDINES AS TOPICAL AGENTS FOR DERMATOLOGICAL APPLICATIONS | Genesis Molecular Technologies, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230374020-A1 | SUBSTITUTED IMIDAZO[l,2-a]PYRAZINES AND PYRAZINO[l,2-a] PYRIMIDINES AS TOPICAL AGENTS FOR DERMATOLOGICAL APPLICATIONS | Genesis Molecular Technologies, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-11639356-B2 | Substituted imidazo[1,2-a]pyrazines and pyrazino[1,2-a]pyrimidines as topical agents for dermatological applications | Genesis Molecular Technologies, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639356-B2 | Substituted imidazo[1,2-a]pyrazines and pyrazino[1,2-a]pyrimidines as topical agents for dermatological applications | Genesis Molecular Technologies, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20220106320-A1 | TOPICAL AGENTS FOR DERMATOLOGICAL APPLICATIONS | Genesis Molecular Technologies, Inc. | 2022-04-07 | — | — | US | disclosed |
| US-9585884-B2 | Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639356-B2 | Substituted imidazo[1,2-a]pyrazines and pyrazino[1,2-a]pyrimidines as topical agents for dermatological applications | CREBBP, CREB1, PRKACA | CLPP 3050/4885CTNNB1 4/4885TCF7 55/4885 |
| US-20220106320-A1 | TOPICAL AGENTS FOR DERMATOLOGICAL APPLICATIONS | CREBBP, EBP, CREB1 | CLPP 2598/4885CTNNB1 6/4885TCF7 74/4885 |
| US-20230374020-A1 | SUBSTITUTED IMIDAZO[l,2-a]PYRAZINES AND PYRAZINO[l,2-a] PYRIMIDINES AS TOPICAL AGENTS FOR DERMATOLOGICAL APPLICATIONS | CREBBP, CREB1, EP300 | CLPP 2590/4885CTNNB1 4/4885TCF7 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.